Gregory Conn - PDS Biotechnology Chief Scientific Officer
| PDSB Stock | USD 2.17 0.08 3.83% |
Executive
Dr. Gregory Conn, Ph.D. is Chief Scientific Officer of the Company. Dr. Conn has more than 35 years of drugdevelopment expertise, including development of antiviral and anticancer drugs through to commercialization. He is a graduate of the Albert Einstein College of Medicine, where he obtained both his M.S. and Ph.D., discovering novel angiogenic molecules in the human brain. Dr. Conn started his pharmaceutical career at Merck, Sharpe, and Dohme, where he continued his work on novel angiogenic factors, discovering and characterizing the VEGF family of growth factors, work which led to the development and commercialization of the anticancer drug Avastin. He was later a leading scientist at Regeneron Pharmaceuticals, where he established and headed various groups in the Cell and Molecular Biology and Drug Discovery departments. Dr. Conn subsequently became a Director in the Process Development department at Covance Biotechnology Services Inc., a contract research and development and drug manufacturing organization, where he supervised the analytical development teams responsible for drug characterization, method development and drug stability studies, and program teams responsible for developing drug manufacturing processes. Dr. Conn has expertise across all phases of the drug development process, including FDA and regulatory requirements, is the coinventor of eight drug patents, and was a founding member of the PDS team as CSO. since 2019.
| Age | 69 |
| Tenure | 5 years |
| Address | 303A College Road East, Princeton, NJ, United States, 08540 |
| Phone | 800 208 3343 |
| Web | https://www.pdsbiotech.com |
PDS Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.3995) % which means that it has lost $0.3995 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.284) %, meaning that it created substantial loss on money invested by shareholders. PDS Biotechnology's management efficiency ratios could be used to measure how well PDS Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.76. In addition to that, Return On Capital Employed is expected to decline to -0.99. At present, PDS Biotechnology's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 63.4 M, whereas Non Current Assets Total are forecasted to decline to about 318.3 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Roman Necina | Hookipa Pharma | 56 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Candice Masse | Elevation Oncology | N/A | |
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Robert Sweeney | Ocean Biomedical | 59 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| JD Esq | Terns Pharmaceuticals | 55 | |
| MD MBA | Ocean Biomedical | 59 | |
| Esq CPA | Ocean Biomedical | 59 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Soojin Kim | Inozyme Pharma | N/A | |
Management Performance
| Return On Equity | -1.28 | ||||
| Return On Asset | -0.4 |
PDS Biotechnology Corp Leadership Team
Elected by the shareholders, the PDS Biotechnology's board of directors comprises two types of representatives: PDS Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PDS. The board's role is to monitor PDS Biotechnology's management team and ensure that shareholders' interests are well served. PDS Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PDS Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lars MBA, Chief Officer | ||
| Joe Dervan, VP Development | ||
| Deanne Randolph, Head Relations | ||
| Gregory Conn, Chief Scientific Officer | ||
| Spencer JD, Senior Counsel | ||
| Nathalie Riebel, VP Operations | ||
| Janetta Trochimiuk, Controller | ||
| MS MBA, Chief Officer | ||
| Sanjay Zaveri, Senior Development | ||
| Kirk MD, Chief Officer | ||
| Frank BeduAddo, President CEO, Director | ||
| Lauren MD, Chief Officer | ||
| Matthew CPA, Principal CFO |
PDS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PDS Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.28 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 53.1 M | ||||
| Shares Outstanding | 37.41 M | ||||
| Shares Owned By Insiders | 3.99 % | ||||
| Shares Owned By Institutions | 12.35 % | ||||
| Number Of Shares Shorted | 4.47 M | ||||
| Price To Earning | 24.70 X | ||||
| Price To Book | 3.55 X | ||||
| EBITDA | (40.08 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.40) | Return On Equity (1.28) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.